---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-26-000058"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2026-08-03T11:04:02+00:00"
generated_at: "2026-08-03T11:05:05.496378+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q2 2026 revenue $119.2M (+24% YoY); net income $54.8M; cash $1.1B

## Summary
- Q2 2026 VYJUVEK global revenue $119.2M, up 24% YoY; gross margin 95%.
- Net income $54.8M ($1.85 basic EPS) vs $38.3M ($1.33) in Q2 2025.
- Cash and investments $1.1B; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.
- KB803 (ophthalmology) IOLITE study fully enrolled; top-line data expected 4Q 2026.
- KB407 (CF) interim results expected before year end; FDA alignment on registrational study design expected 4Q 2026.

## SEC filing metadata
- accession: 0001711279-26-000058
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2026-08-03T11:04:02+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/0001711279-26-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/krys-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-26-000058
- JSON: https://secwatch.observer/filing/0001711279-26-000058.json
- Plain text: https://secwatch.observer/filing/0001711279-26-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.